MKD is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment plans for treatment and management of MKD require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in conditions. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of MKD. The platform serves a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity in China.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.